Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTAZICEF (ceftazidime) by Pfizer is [ see clinical pharmacology ( ) ]. Approved for the following infections caused by designated susceptible gram-negative microorganisms in adult, used in combination with metronidazole ( ) complicated urinary tract infections (cuti), including pyelonephritis ( ) hospital-acquired bacterial pneumonia and 19 more indications. First approved in 1986.
Drug data last refreshed 19h ago
[ see Clinical Pharmacology ( ) ].
Worked on TAZICEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Real-World Study of Ceftazidime Avibactam in China
Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo